surmount-1 tirzepatide weight loss nondiabetic SURMOUNT-1: In an RCT, adults with obesity treated with weekly had major over 72 weeks. #ADA2022 https://t.co/X2RrvYxzsV SURMOUNT-1 Trial - Cardionerds Twitter

While there is limited research on combining the two, its important to consult with a healthcare provider before starting both

You can read the full article at Tirzepatide, a new dual GIP/GLP-1 receptor agonist administered once weekly, is currently being developed as a treatment for type 2 diabetes (T2D) and obesity

Killick, R., Fearnhead, P

Nevertheless, given its novelty, further investigation is required to gain a comprehensive understanding of its potential adverse effects [10]

How long to stay on semaglutide is a question many people ask, and the answer for most is indefinitely, at a maintenance dose that preserves results while minimizing side effects